Bimekizumab is a Monoclonal Antibody owned by UCB, and is involved in 40 clinical trials, of which 33 were completed, 6 are ongoing, and 1 is planned.

Bimekizumab acts by inhibiting interleukin- 17A and L-17F. Interleukin- 17 is an cytokine. IL-17 expression is detectable in biopsies from lesional psoriatic skin. IL-17 has also been implicated in inflammatory skin diseases. IL-17 enhances the neutrophil chemotaxis.

The revenue for Bimekizumab is expected to reach a total of $36bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bimekizumab NPV Report.

Bimekizumab is originated and owned by UCB.

Bimekizumab Overview

Bimekizumab (Bimzelx) is a humanised IgG1monoclonal antibody produced in a genetically engineered Chinese hamster ovary (CHO) cell line by recombinant DNA technology. It is formulated as solution for injection in pre-filled syringe and pre-filled pen for subcutaneous route of administration. Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimzelx is indicated for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments

Bimekizumab (UCB-4940) is under development for the treatment of immunological diseases including non-radiographic axial spondyloarthritis, ankylosing spondylitis, plaque psoriasis, hidradenitis suppurativa and psoriatic arthritis. The drug candidate is a new biological entity (Nbe). It is administered intravenously and as subcutaneous solution. The therapeutic candidate is a humanized monoclonal antibody against IL17A and IL17F. It was also under development for the treatment of non-radiographic axial spondyloarthritis, ankylosing spondylitis, rheumatoid arthritis and moderate to severe active ulcerative colitis (intravenous).

UCB Overview

UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

The company reported revenues of (Euro) EUR5,777 million for the fiscal year ended December 2021 (FY2021), an increase of 8% over FY2020. In FY2021, the company’s operating margin was 22.2%, compared to an operating margin of 18.2% in FY2020. In FY2021, the company recorded a net margin of 18.3%, compared to a net margin of 13.7% in FY2020.

Quick View – Bimekizumab

Report Segments
  • Innovator (NME)
Drug Name
  • Bimekizumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immunology
  • Musculoskeletal Disorders
Key Companies
  • Sponsor Company: UCB
  • Originator: UCB
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.